Objetivo Peri-implant disease (Mucositis and peri-implantitis) is a major and growing clinical problem in odontology, affecting 20-40mill. patients in Europe, and the double worldwide. Labrida has developed, clinically documented and CE marked a novel,patented (pending) maintenance device for non-surgical management of peri-implant disease. It is a revision brush(“BioClean”), with bioresorbable bristles made of mono-filament chitosan fibres (Patented by Medovent, DE). It offers safer,more effective, less painful and faster treatment of peri-implant disease, where currently the clinical community is in searchfor adequate solutions. The instrument addresses a market in the range of Euro 1-2 billion annual turnover.The device is in small scale production and sold commercially in Scandinavia (TRL 7), with most promising market response.To meet the market opportunity, we will develop up-scaled production processes of advanced chitosan fibres, which iscritical to increase overall production requirements. In addition, we have started development with clinical pilot testing of thenext generation product, comprising chitosan bristles combined with antibiotics, with interesting clinical results. This mayopen a broader application field for deployment of these combinations of materials technologies, both within odontology andwider in medicine.The overall planned project (Phase 2) comprises both industrial development of scaled up production technologies for thechitosan fibres of the currently marketed product , as well as development of the next generation product, combiningadvanced chitosan technologies with bioactive material, e.g. in nanospheres. In phase 1, we intend to refine thedevelopment plan of these product(s) for phase 2, including assessing more in detail the business case, and additionalapplication areas, of the 2nd generation product. Ámbito científico medical and health sciencesclinical medicinegeneral medicine Programa(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2014 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador LABRIDA AS Aportación neta de la UEn € 50 000,00 Dirección Theodor lovstads vei 32 0286 Oslo Noruega Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Norge Oslo og Viken Oslo Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00